Document Detail


Long-term immunologic outcome in HAART-experienced subjects receiving lopinavir/ritonavir.
MedLine Citation:
PMID:  17147495     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The long-term immunological efficacy of regimens including lopinavir/ritonavir (LPV/r) has not been assessed in HIV-infected HAART-experienced subjects. The present study included 452 consecutive HIV-infected outpatients starting LPV/r before May 2003 after failing (HIV-RNA > 1000 copies/ml) HAART. Four groups were considered according to CD4 cell counts at LPV/r initiation: group 1 (G1, n = 115) < 100 cells/mm(3); group 2 (G2, n = 113) 100-199 cells/mm(3); group 3 (G3, n = 115) 200-349 cells/mm(3); group 4 (G4, n = 109) >/= 350 cells/mm(3). The majority of patients were males (n = 320, 70.8%), the median age was 38 years, and 180 (39.6%) were on CDC stage C. The median time of previous HAART was 51.1 months (12-81.7) and a median of 7 antiretroviral regimens and of 3 protease inhibitors was changed before LPV/r. The mean CD4 cell count increase was 105, 113, 128, and 144 cells/mm(3) after 12 months (p < 0.01 for each group) and 128, 106, 90, and 100 cells/mm(3) at month 48 (p < 0.01 for each group) in G1, G2, G3, and G4, respectively. The mean increase was comparable among the four groups. The on treatment analysis showed a better immunologic response among G1 and G2 patients from month 36. Forty-seven patients (10.4%), mainly in G1 and G2, maintained LPV/r despite persistent HIV-RNA > 1000 copies/ml. A mean increase of 64 and 65 cells/mm(3) and of 88 and 56 cells/mm(3) at month 12 and 48 was observed in G1 and G2, respectively. The use of LPV/r-based regimens also provided a durable immunologic recovery in highly pretreated HIV-infected subjects.
Authors:
Marco Bongiovanni; Teresa Bini; Maddalena Casana; Paola Cicconi; Federica Tordato; Antonella D'Arminio Monforte
Related Documents :
19157955 - Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell ...
3978715 - Intracellular and secreted proteins of density-inhibited, serum-arrested and proliferat...
2147225 - Cell cycle arrest caused by cln gene deficiency in saccharomyces cerevisiae resembles s...
8575465 - Localization of proteasomal antigens during different phases of the cell cycle in hela ...
17659385 - The evaluation of a semiautomated computer method to determine the effects of dmso on g...
22954255 - A possible primary cause of cancer: deficient cellular interactions in endocrine pancreas.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  AIDS research and human retroviruses     Volume:  22     ISSN:  0889-2229     ISO Abbreviation:  AIDS Res. Hum. Retroviruses     Publication Date:  2006 Nov 
Date Detail:
Created Date:  2006-12-06     Completed Date:  2007-01-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8709376     Medline TA:  AIDS Res Hum Retroviruses     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1096-105     Citation Subset:  IM; X    
Affiliation:
Clinic of Infectious Diseases, San Paolo Hospital, University of Milan, Milan, Italy. marco.bongiovanni@unimi.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anti-HIV Agents / adverse effects,  therapeutic use*
Antiretroviral Therapy, Highly Active*
CD4 Lymphocyte Count
Female
HIV Infections / drug therapy*,  immunology*
Humans
Male
Middle Aged
Pyrimidinones / adverse effects,  therapeutic use*
Retrospective Studies
Ritonavir / adverse effects,  therapeutic use*
Time Factors
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Pyrimidinones; 0/Ritonavir; 192725-17-0/lopinavir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interf...
Next Document:  Reduced aerobic capacity and physical functioning in older HIV-infected men.